Oct 8, 2018   SOURCE: PR NewsWire

2018 Pain Drug Development Pipeline Review: Post-Operative Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS) and Visceral Pain

DUBLIN, Oct. 8, 2018 /PRNewswire/ --

The "Pain Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.

Causes of post-operative pain include peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics. There are 74 products in development for this indication.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. There are 21 products in development for this indication.

CRPS is a chronic pain condition that most often affects one limb, usually after an injury. CRPS is divided into two types: CRPS-I (individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in the affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams. There are 7 products in development for this indication.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or nonsteroidal anti-inflammatory drugs and pain modifiers such as tricyclic antidepressants or anticonvulsants. There are 38 products in development for this indication.

Molecular targets acted on by products in development for pain disorders include beta nerve growth factor, cannabinoid receptors, opioid receptors and protein kinases. Companies operating in this pipeline space include NeurAxon, Abide Therapeutics and Pfizer.

Scope

    --  Which companies are the most active within each pipeline?
    --  Which pharmaceutical approaches are the most prominent at each stage of
        the pipeline and within each indication?
    --  To what extent do universities and institutions play a role within this
        pipeline, compared to pharmaceutical companies?
    --  What are the most important R&D milestones and data publications to have
        happened in this disease area?

Key Topics Covered

1 Table of Contents

2 Introduction

2.1 Pain Report Coverage
2.2 Post-Operative Pain - Overview
2.3 Fibromyalgia - Overview
2.4 Complex Regional Pain Syndrome - Overview
2.5 Visceral Pain - Overview

3 Therapeutics Development

3.1 Post-Operative Pain
3.2 Fibromyalgia
3.3 Complex Regional Pain Syndrome
3.4 Visceral Pain

4 Therapeutics Assessment

4.1 Post-Operative Pain
4.2 Fibromyalgia
4.3 Complex Regional Pain Syndrome
4.4 Visceral Pain

5 Companies Involved in Therapeutics Development

5.1 Post-Operative Pain
5.2 Fibromyalgia
5.3 Complex Regional Pain Syndrome
5.4 Visceral Pain

6 Dormant Projects

6.1 Post-Operative Pain
6.2 Fibromyalgia
6.3 Complex Regional Pain Syndrome
6.4 Visceral Pain

7 Discontinued Products

7.1 Post-Operative Pain
7.2 Fibromyalgia
7.3 Visceral Pain

8 Product Development Milestones

8.1 Post-Operative Pain
8.2 Fibromyalgia
8.3 Complex Regional Pain Syndrome
8.4 Visceral Pain

Companies Featured

    --  Abide Therapeutics Inc
    --  Abiogen Pharma SpA
    --  AcelRx Pharmaceuticals Inc
    --  Addex Therapeutics Ltd
    --  Adynxx Inc
    --  Anavex Life Sciences Corp
    --  AngioChem Inc
    --  Aoxing Pharmaceutical Company Inc
    --  Apsen Farmaceutica SA
    --  Aptinyx Inc
    --  Arena Pharmaceuticals Inc
    --  Artelo Biosciences Inc
    --  Astellas Pharma Inc
    --  Cadila Healthcare Ltd
    --  Camurus AB
    --  Cara Therapeutics Inc
    --  Center Laboratories Inc
    --  CerSci Therapeutics Inc
    --  Chromocell Corp
    --  Colby Pharmaceutical Co
    --  Daiichi Sankyo Co Ltd
    --  Dompe Farmaceutici SpA
    --  Echo Pharmaceuticals BV
    --  Eisai Co Ltd
    --  Eli Lilly and Co
    --  Eupraxia Pharmaceuticals Inc
    --  EyeGate Pharmaceuticals Inc
    --  Fujimoto Pharmaceutical Corp
    --  Grunenthal GmbH
    --  GW Pharmaceuticals Plc
    --  Heron Therapeutics Inc
    --  Idera Pharmaceuticals Inc
    --  Immupharma Plc
    --  Innocoll AG
    --  Innovative Med Concepts LLC
    --  Insys Therapeutics Inc
    --  Intec Pharma Ltd
    --  Ionis Pharmaceuticals Inc
    --  Ironwood Pharmaceuticals Inc
    --  iX Biopharma Ltd
    --  Jiangsu Hengrui Medicine Co Ltd
    --  Kyorin Pharmaceutical Co Ltd
    --  Kytogenics Pharmaceuticals Inc
    --  Lipella Pharmaceuticals Inc
    --  Lipocure Ltd
    --  Liquidia Technologies Inc
    --  Lumosa Therapeutics Co Ltd
    --  Luye Pharma Group Ltd
    --  Medtronic Plc
    --  Merck & Co Inc
    --  Mundipharma International Ltd
    --  Neumentum Inc
    --  Novartis AG
    --  Ocular Therapeutix Inc
    --  Pacira Pharmaceuticals Inc
    --  PainReform Ltd
    --  Pfizer Inc
    --  Pharmaleads SA
    --  PhytoHealth Corp
    --  Piramal Enterprises Ltd
    --  PixarBio Corp
    --  PolyPid Ltd
    --  Prismic Pharmaceuticals Inc
    --  RaQualia Pharma Inc
    --  Recro Pharma Inc
    --  Serina Therapeutics Inc
    --  SteadyMed Therapeutics Inc
    --  Taiwan Liposome Company Ltd
    --  Teikoku Pharma USA Inc
    --  Tetra Bio-Pharma Inc
    --  Trevena Inc
    --  UCB SA
    --  Urigen Pharmaceuticals Inc
    --  Virpax Pharmaceuticals Inc
    --  Vitality Biopharma Inc
    --  Xigen SA
    --  YiChang Humanwell Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/6qw6pg/2018_pain_drug?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2018-pain-drug-development-pipeline-review-post-operative-pain-fibromyalgia-complex-regional-pain-syndrome-crps-and-visceral-pain-300725314.html

SOURCE Research and Markets